Mesoblast (ASX:MSB) Issuance of Debt : A$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Mesoblast Issuance of Debt?

Mesoblast's Issuance of Debt for the three months ended in Dec. 2024 was A$0.00 Mil.

Mesoblast's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil.

Mesoblast Issuance of Debt Historical Data

The historical data trend for Mesoblast's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Issuance of Debt Chart

Mesoblast Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Issuance of Debt

Get a 7-Day Free Trial

0.74

73.88

Mesoblast Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Issuance of Debt	Get a 7-Day Free Trial															-	-	-	-	-

Mesoblast Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Mesoblast Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Mesoblast's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (ASX:MSB) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

MEOBF:USA MESO:USA LWB:Germany LWB1:Germany

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.